CN113717272A - Freeze-drying protective agent for improving stability of recombinant human collagen - Google Patents
Freeze-drying protective agent for improving stability of recombinant human collagen Download PDFInfo
- Publication number
- CN113717272A CN113717272A CN202110954486.2A CN202110954486A CN113717272A CN 113717272 A CN113717272 A CN 113717272A CN 202110954486 A CN202110954486 A CN 202110954486A CN 113717272 A CN113717272 A CN 113717272A
- Authority
- CN
- China
- Prior art keywords
- freeze
- recombinant human
- human collagen
- drying
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 63
- 108010035532 Collagen Proteins 0.000 title claims abstract description 63
- 229920001436 collagen Polymers 0.000 title claims abstract description 63
- 238000004108 freeze drying Methods 0.000 title claims abstract description 33
- 239000003223 protective agent Substances 0.000 title claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 25
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 12
- 229930195725 Mannitol Natural products 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 12
- 239000000594 mannitol Substances 0.000 claims abstract description 12
- 235000010355 mannitol Nutrition 0.000 claims abstract description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 12
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920003081 Povidone K 30 Polymers 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 7
- 241000235058 Komagataella pastoris Species 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 9
- 230000007774 longterm Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a freeze-drying protective agent for improving the stability of recombinant human collagen. The protective agent comprises 100 parts by weight of recombinant human collagen, 500 parts by weight of trehalose, 500 parts by weight of polyvinylpyrrolidone (PVP-K30) and 100 parts by weight of mannitol. In the freeze-drying process of the recombinant human collagen, the freeze-drying protective agent is added, so that the stability of the recombinant human collagen freeze-dried powder at normal temperature can be obviously improved, the purity and activity of the recombinant human collagen freeze-dried powder are prevented from being reduced, and the prepared freeze-dried powder can be placed at normal temperature for a long time.
Description
Technical Field
The invention belongs to the technical field of preservation of biological products, and relates to a freeze-drying protective agent for improving the stability of recombinant human collagen.
Background
The recombinant human collagen is based on the original gene sequence of human skin collagen, and the parts with strong water solubility and high biological activity are optimized and selected for codon optimization and splicing recombination to obtain a brand new recombinant human collagen sequence. The collagen has good water solubility and high bioactivity, has better performance than animal-derived collagen, and has wide application prospect in the field of biomedical materials.
Because the recombinant human collagen aqueous solution has poor stability and is sensitive to heat, the recombinant human collagen aqueous solution is generally prepared into freeze-dried powder by a freeze-drying method, and is convenient to store and use. However, the freeze-drying process causes the natural structure of the recombinant protein to be denatured because the surface of the recombinant collagen in the aqueous solution forms a hydrated layer, and the water removed by the drying process destroys the hydrogen bonding structure of the protein surface. In addition, the freeze-dried recombinant human collagen needs to be frozen or refrigerated for storage, and is easy to degrade and lower in purity when stored at normal temperature (25 ℃), so that the application of the recombinant human collagen is restricted to a certain extent.
Disclosure of Invention
The invention aims to provide a freeze-drying protective agent for improving the stability of recombinant human collagen. The protective freeze-drying agent can improve the stability of the recombinant human collagen freeze-dried powder at normal temperature and prevent the purity and activity of the recombinant human collagen freeze-dried powder from being reduced.
In order to achieve the purpose, the technical scheme of the invention is as follows:
the freeze-drying protective agent for improving the stability of the recombinant human collagen comprises 100 parts of the recombinant human collagen by weight and comprises the following components: 500 portions of trehalose, 500 portions of polyvinylpyrrolidone (PVP-K30) and 200 portions of mannitol.
The recombinant human collagen is produced by fermenting pichia pastoris with the preservation number of CGMCC NO.5021 and is fully disclosed in Chinese patent ZL 201110327865.5.
Preferably, the lyoprotectant consists of the following components: 1000 parts of trehalose, 200 parts of polyvinylpyrrolidone (PVP-K30) and 200 parts of mannitol.
Further, the application method of the freeze-drying protective agent comprises the following steps: weighing recombinant human collagen, trehalose, polyvinylpyrrolidone (PVP-K30) and mannitol according to a proportion, adding injection water until the mixture is completely dissolved, adopting a filter membrane of 0.22 mu m for sterilization and filtration, subpackaging in penicillin bottles, and then putting into a freeze dryer for freeze drying to obtain the recombinant human collagen freeze-dried powder.
Compared with the prior art, the invention has the following remarkable effects:
according to the invention, the formula of the freeze-drying protective agent is reasonably matched, and the protective agent trehalose, polyvinylpyrrolidone and excipient mannitol are added. The trehalose can improve the glass transition temperature, and can be used as a low-temperature protective agent in the freezing process and a dehydration protective agent in the drying and dehydration process to protect the hydrogen bond structure on the surface of the protein. The polyvinylpyrrolidone can form a heat-resistant framework, reduce the influence of heat radiation on the recombinant human collagen, and slow down the degradation of protein at normal temperature. The two protective agents have different protective mechanisms for protecting proteins at different stages of freeze drying, and have synergistic protective effect on recombinant human collagen when used together. The freeze-drying protective agent can effectively enhance the resistance of the recombinant human collagen to the adverse environment of drying and normal temperature, reduces the degradation amplitude of the product purity, ensures that the shelf life of the freeze-dried powder can reach one year at normal temperature (25 ℃), improves the stability of the product, solves the problem that the freeze-dried powder needs to be stored and transported at low temperature, and is beneficial to popularization and application of the product.
Detailed Description
The present invention will be described in more detail with reference to specific examples.
In the following examples, the concentration of the recombinant human collagen solution used was 1 wt.% and the purity was 100%.
Example 1
The preparation method of the recombinant human collagen freeze-dried powder comprises the following steps:
1. 50g of trehalose, 10g of polyvinylpyrrolidone (PVP-K30) and 10g of mannitol are accurately weighed and dissolved by adding 300g of water for injection.
2. Accurately weighing 500g of recombinant human collagen solution containing 5g of recombinant human collagen, uniformly mixing the solution with the solution obtained in the step 1, and then adding water for injection, wherein the total weight is 1000 g.
3. The solution of step 2 was sterile filtered through a 0.22 μm filter to obtain a filtrate.
4. And (4) subpackaging the filtrate obtained in the step (3) in a tube-type bottle, half plugging, and freeze-drying in a freeze-drying machine.
5. After the freeze drying is finished, performing vacuum tamponade, capping and labeling to obtain the recombinant human collagen freeze-dried powder, and placing the recombinant human collagen freeze-dried powder in a stability incubator with the temperature of 25 ℃ and the humidity of 60% to perform a long-term stability experiment.
6. Purity was checked every 3 months and changes were observed.
Examples 2 to 5
The examples are essentially the same as example 1, except that the lyoprotectant employed contains different amounts of the components, as detailed in Table 1.
TABLE 1 amount of each raw material added in each example
Comparative example 1
This comparative example is essentially the same as example 1 except that no lyoprotectant was added.
The preparation method of the recombinant human collagen freeze-dried powder comprises the following steps:
1. 500g of recombinant human collagen solution containing 5g of recombinant human collagen is accurately weighed, and then 500g of water for injection is added, wherein the total weight is 1000 g.
2. The solution of step 1 was sterile filtered through a 0.22 μm filter to obtain a filtrate.
3. And (3) subpackaging the filtrate obtained in the step (2) in a tube-type bottle, half plugging, and freeze-drying in a freeze-drying machine.
4. After the freeze drying is finished, performing vacuum tamponade, capping and labeling to obtain the recombinant human collagen freeze-dried powder, and placing the recombinant human collagen freeze-dried powder in a stability incubator with the temperature of 25 ℃ and the humidity of 60% to perform a long-term stability experiment.
5. Purity was checked every 3 months and changes were observed.
Comparative example 2
This comparative example is substantially the same as example 1 except for the content of each component in the lyoprotectant.
The preparation method of the recombinant human collagen freeze-dried powder comprises the following steps:
1. 125g of trehalose, 30g of polyvinylpyrrolidone (PVP-K30) and 10g of mannitol are accurately weighed and dissolved by adding 300g of water for injection.
2. Accurately weighing 500g of recombinant human collagen solution containing 5g of recombinant human collagen, uniformly mixing the solution with the solution obtained in the step 1, and then adding water for injection, wherein the total weight is 1000 g.
3. The solution of step 2 was sterile filtered through a 0.22 μm filter to obtain a filtrate.
4. And (4) subpackaging the filtrate obtained in the step (3) in a tube-type bottle, half plugging, and freeze-drying in a freeze-drying machine.
5. After the freeze drying is finished, performing vacuum tamponade, capping and labeling to obtain the recombinant human collagen freeze-dried powder, and placing the recombinant human collagen freeze-dried powder in a stability incubator with the temperature of 25 ℃ and the humidity of 60% to perform a long-term stability experiment.
6. Purity was checked every 3 months and changes were observed.
Comparative example 3
This comparative example is substantially the same as example 1 except for the kinds and contents of the components in the lyoprotectant.
The preparation method of the recombinant human collagen freeze-dried powder comprises the following steps:
1. accurately weighing 50g of trehalose and 10g of mannitol, and adding 300g of water for injection to dissolve.
2. Accurately weighing 500g of recombinant human collagen solution containing 5g of recombinant human collagen, uniformly mixing the solution with the solution obtained in the step 1, and then adding water for injection, wherein the total weight is 1000 g.
3. The solution of step 2 was sterile filtered through a 0.22 μm filter to obtain a filtrate.
4. And (4) subpackaging the filtrate obtained in the step (3) in a tube-type bottle, half plugging, and freeze-drying in a freeze-drying machine.
5. After the freeze drying is finished, performing vacuum tamponade, capping and labeling to obtain the recombinant human collagen freeze-dried powder, and placing the recombinant human collagen freeze-dried powder in a stability incubator with the temperature of 25 ℃ and the humidity of 60% to perform a long-term stability experiment.
6. Purity was checked every 3 months and changes were observed.
Comparative example 4
This comparative example is substantially the same as example 1 except for the kinds and contents of the components in the lyoprotectant.
The preparation method of the recombinant human collagen freeze-dried powder comprises the following steps:
1. 10g of polyvinylpyrrolidone (PVP-K30) and 10g of mannitol are accurately weighed and dissolved by adding 300g of water for injection.
2. Accurately weighing 500g of recombinant human collagen solution containing 5g of recombinant human collagen, uniformly mixing the solution with the solution obtained in the step 1, and then adding water for injection, wherein the total weight is 1000 g.
3. The solution of step 2 was sterile filtered through a 0.22 μm filter to obtain a filtrate.
4. And (4) subpackaging the filtrate obtained in the step (3) in a tube-type bottle, half plugging, and freeze-drying in a freeze-drying machine.
5. After the freeze drying is finished, performing vacuum tamponade, capping and labeling to obtain the recombinant human collagen freeze-dried powder, and placing the recombinant human collagen freeze-dried powder in a stability incubator with the temperature of 25 ℃ and the humidity of 60% to perform a long-term stability experiment.
6. Purity was checked every 3 months and changes were observed.
The purity (%) of the recombinant human collagen lyophilized powder prepared according to various proportions and embodiments is shown in table 2, and the detection method is shown in chinese patent application CN 109481335A.
TABLE 2 Long-term stability test purity test results
| Time of standing | Comparative example 1 | Comparative example 2 | Comparative example 3 | Comparative example 4 | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 |
| 0 month | 99.3％ | 100％ | 100％ | 99.6％ | 100％ | 100％ | 100％ | 100％ | 100％ |
| 3 month | 97.1％ | 99.2％ | 99.1％ | 99.3％ | 100％ | 99.8％ | 99.6％ | 100％ | 100％ |
| 6 month | 95.8％ | 98.3％ | 98.0％ | 98.4％ | 99.4％ | 99.3％ | 99.8％ | 99.6％ | 99.5％ |
| 9 month | 93.9％ | 97.5％ | 97.2％ | 97.8％ | 99.6％ | 99.4％ | 99.4％ | 99.6％ | 99.2％ |
| 12 month | 92.8％ | 96.8％ | 96.2％ | 96.5％ | 99.6％ | 98.3％ | 99％ | 99.2％ | 98.7％ |
As can be seen from Table 2, through long-term stability observation, the purity of the recombinant human collagen lyophilized powder prepared in 5 examples is obviously higher than that of comparative examples 1-4 after being stored at room temperature for 12 months, which indicates that the purity of the recombinant human collagen lyophilized powder protected by the cryoprotectant of the invention is not obviously reduced within 12 months and the quality is stable under the condition of normal temperature (25 ℃).
Claims (4)
1. The freeze-drying protective agent for improving the stability of the recombinant human collagen is characterized by comprising the following components in parts by weight, taking the recombinant human collagen as 100 parts: 500 portions of trehalose, 500 portions of polyvinylpyrrolidone (PVP-K30) and 200 portions of mannitol.
2. The lyoprotectant according to claim 1, wherein the recombinant human collagen is produced by fermentation of Pichia pastoris with accession number CGMCC No. 5021.
3. The lyoprotectant of claim 1, wherein said lyoprotectant comprises the following components: 1000 parts of trehalose, 200 parts of polyvinylpyrrolidone (PVP-K30) and 200 parts of mannitol.
4. The lyoprotectant of claim 1, wherein said lyoprotectant is administered by a method comprising: weighing recombinant human collagen, trehalose, polyvinylpyrrolidone (PVP-K30) and mannitol according to a proportion, adding injection water until the mixture is completely dissolved, adopting a filter membrane of 0.22 mu m for sterilization and filtration, subpackaging in penicillin bottles, and then putting into a freeze dryer for freeze drying to obtain the recombinant human collagen freeze-dried powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110954486.2A CN113717272B (en) | 2021-08-19 | 2021-08-19 | Freeze-drying protective agent for improving stability of recombinant human collagen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110954486.2A CN113717272B (en) | 2021-08-19 | 2021-08-19 | Freeze-drying protective agent for improving stability of recombinant human collagen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113717272A true CN113717272A (en) | 2021-11-30 |
| CN113717272B CN113717272B (en) | 2023-09-05 |
Family
ID=78676774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110954486.2A Active CN113717272B (en) | 2021-08-19 | 2021-08-19 | Freeze-drying protective agent for improving stability of recombinant human collagen |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113717272B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114010528A (en) * | 2021-12-20 | 2022-02-08 | 广州栋方生物科技股份有限公司 | Recombinant human collagen freeze-dried powder and preparation method thereof |
| CN115252899A (en) * | 2022-09-13 | 2022-11-01 | 济南之羽医疗科技有限公司 | Freeze-dried powder containing recombinant human collagen and preparation method thereof |
| CN115944571A (en) * | 2023-01-10 | 2023-04-11 | 河北纳科生物科技有限公司 | Essence spray for promoting hair growth and repairing hair roots and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1912667A2 (en) * | 2005-07-22 | 2008-04-23 | Amgen, Inc | Concentrated protein lyophilates, methods, and uses |
| CN102443057A (en) * | 2011-10-26 | 2012-05-09 | 南京理工大学 | Recombinant humanized collagen and its preparation method |
| WO2015010092A1 (en) * | 2013-07-18 | 2015-01-22 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| CN105012963A (en) * | 2015-08-19 | 2015-11-04 | 肇庆大华农生物药品有限公司 | Heat-resisting lyophilized protector for recombinant pseudorabies virus vaccine and preparation method of heat-resisting lyophilized protector |
| CN107281481A (en) * | 2017-08-02 | 2017-10-24 | 华派生物工程集团有限公司 | A kind of pseudo- mad dog heat-resisting lyophilized protecting agent of live vaccine, preparation method and freeze dried vaccine and preparation method |
| CN108085256A (en) * | 2016-11-22 | 2018-05-29 | 深圳华大三生园科技有限公司 | A kind of freeze drying protectant and its application |
| CN111671667A (en) * | 2020-06-30 | 2020-09-18 | 广东众尔健生物科技有限公司 | Active collagen freeze-dried powder and preparation method thereof |
| CN112972662A (en) * | 2021-01-27 | 2021-06-18 | 武汉爱博泰克生物科技有限公司 | Freeze-drying protective agent for protease K, and preparation method and application thereof |
-
2021
- 2021-08-19 CN CN202110954486.2A patent/CN113717272B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1912667A2 (en) * | 2005-07-22 | 2008-04-23 | Amgen, Inc | Concentrated protein lyophilates, methods, and uses |
| CN102443057A (en) * | 2011-10-26 | 2012-05-09 | 南京理工大学 | Recombinant humanized collagen and its preparation method |
| WO2015010092A1 (en) * | 2013-07-18 | 2015-01-22 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| CN105012963A (en) * | 2015-08-19 | 2015-11-04 | 肇庆大华农生物药品有限公司 | Heat-resisting lyophilized protector for recombinant pseudorabies virus vaccine and preparation method of heat-resisting lyophilized protector |
| CN108085256A (en) * | 2016-11-22 | 2018-05-29 | 深圳华大三生园科技有限公司 | A kind of freeze drying protectant and its application |
| CN107281481A (en) * | 2017-08-02 | 2017-10-24 | 华派生物工程集团有限公司 | A kind of pseudo- mad dog heat-resisting lyophilized protecting agent of live vaccine, preparation method and freeze dried vaccine and preparation method |
| CN111671667A (en) * | 2020-06-30 | 2020-09-18 | 广东众尔健生物科技有限公司 | Active collagen freeze-dried powder and preparation method thereof |
| CN112972662A (en) * | 2021-01-27 | 2021-06-18 | 武汉爱博泰克生物科技有限公司 | Freeze-drying protective agent for protease K, and preparation method and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| FAKES MG, ET AL.: "Moisture sorption behavior of selected bulking agents used in lyophilized products", 《PDA J PHARM SCI TECHNOL》 * |
| HUYGE K, ET AL.: "Suitability of differently formulated dry powder Newcastle disease vaccines for mass vaccination of poultry", 《EUR J PHARM BIOPHARM》 * |
| 余丙洁: "多肽类药物冻干制剂的稳定性研究进展", 《中国生物工程学会2014年学术年会暨全国生物技术大会论文集中国生物工程学会会议论文集》 * |
| 薛菲: "蛋白质的冻干保护剂及其保护机制研究进展", 《中国药学杂志》 * |
| 赵凡: "真空冷冻干燥技术在疫苗研发与生产中的应用", 《真空》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114010528A (en) * | 2021-12-20 | 2022-02-08 | 广州栋方生物科技股份有限公司 | Recombinant human collagen freeze-dried powder and preparation method thereof |
| CN114010528B (en) * | 2021-12-20 | 2023-09-15 | 广州栋方生物科技股份有限公司 | Recombinant human collagen freeze-dried powder and preparation method thereof |
| CN115252899A (en) * | 2022-09-13 | 2022-11-01 | 济南之羽医疗科技有限公司 | Freeze-dried powder containing recombinant human collagen and preparation method thereof |
| CN115252899B (en) * | 2022-09-13 | 2024-03-26 | 济南之羽医疗科技有限公司 | Freeze-dried powder containing recombinant human collagen and preparation method thereof |
| CN115944571A (en) * | 2023-01-10 | 2023-04-11 | 河北纳科生物科技有限公司 | Essence spray for promoting hair growth and repairing hair roots and preparation method thereof |
| CN115944571B (en) * | 2023-01-10 | 2024-04-02 | 河北纳科生物科技有限公司 | Essence spray for promoting hair growth and repairing hair roots and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113717272B (en) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113717272A (en) | Freeze-drying protective agent for improving stability of recombinant human collagen | |
| CN1152713C (en) | Dried blood factor composition comprising trehalose | |
| CN102727903B (en) | Heatproof lyophilized protective agent for live vaccine JXA1-R strain for highly pathogenic porcine reproductive and respiratory syndrome and method for preparing the same | |
| CN106237339B (en) | A kind of freeze dried vaccine heat resisting protective and its preparation method and application | |
| CN106063933B (en) | Universal vaccine freeze-drying protective agent and application thereof | |
| CN102228687B (en) | Freeze-dried live attenuated hepatitis A vaccine not containing gelatin or human albumin protective agent and preparation method for freeze-dried live attenuated hepatitis A vaccine | |
| CN101249043B (en) | Applications of human growth hormone and human epidermal growth factor combination in beauty treatment | |
| CN101074202A (en) | Production of injecting reductive glutathione | |
| CN101693016B (en) | Universal pharmaceutical formulation for recombined human serum albumin fusion proteins for injection | |
| CN109055227B (en) | Protective agent for freeze-drying preservation of genetically engineered strain and preservation method thereof | |
| CN102228444A (en) | N(2)-L-alanyl-L-glutamine preparation for injection and preparation method thereof | |
| CN110590932A (en) | Preparation method of umbilical cord mesenchymal stem cell factor freeze-dried powder | |
| CN109395074A (en) | A kind of encephalitis B inactivated vaccine lyophilized preparation and preparation method thereof | |
| US5714458A (en) | Stable pharmaceutical compositions containing a fibroblast growth factor | |
| CN105999281B (en) | Birds live virus freeze drying protectant, preparation method and application | |
| AU659997B2 (en) | Stable pharmaceutical compositions containing a fibroblast growth factor | |
| CN113576944B (en) | Freeze-dried ball, preparation method thereof and skin care product | |
| CN110151566A (en) | A kind of skin care freeze-dried powder of the polypeptide containing pigskin collagen and its preparation | |
| CN103585633A (en) | Freeze-drying protective agent for recombinant porcine interferon alpha 1 and preparation method thereof | |
| CN114931648A (en) | Heat-resistant protective agent for porcine epidemic diarrhea and porcine transmissible gastroenteritis dual live vaccine and preparation method and application thereof | |
| CN102028661B (en) | Pegylated recombinant human granulocyte colony stimulating factor freeze-dried powder/injection and preparation method thereof | |
| CN112485451A (en) | Interleukin 6 freeze-drying calibrator, preparation method thereof and freeze-drying protective solution | |
| CN107349230A (en) | A kind of fresh cordyceps sinensis product and preparation method thereof | |
| CN1318087C (en) | Removing albumin nerve growth factor agent | |
| CN102327239A (en) | Salmon calcitonin nano liposome injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |